We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ME1 market cap is 176.66k. The company's latest EPS is AUD -0.4453 and P/E is 0.00.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 4.49M | 3.54M | 6.25M | 8.94M | 21.82M |
| Operating Income | -13.16M | -20.14M | -28.32M | -31.46M | -38.94M |
| Net Income | -15.05M | -30.8M | -30.03M | -32.78M | -52.45M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 22.66M | 19.12M | 29.31M | 37.98M | 19.04M |
| Total Liabilities | 5.39M | 5.47M | 1.56M | 15.69M | 23.1M |
| Total Equity | 17.27M | 13.65M | 27.76M | 22.29M | -4.06M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -10.17M | -9.62M | -22.38M | -17.31M | -8.14M |
| Investing | -3.34M | -831k | -1.37M | -2.28M | -81k |
| Financing | 10.04M | 13.65M | 24.89M | 13.81M | 7.51M |
| Market Cap | 176.66k |
| Price to Earnings Ratio | 0.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 117.77M |
| Average Volume (1 week) | 17.1M |
| Average Volume (1 Month) | 14.11M |
| 52 Week Change | -85.00% |
| 52 Week High | 0.017 |
| 52 Week Low | 0.001 |
| Spread (Intraday) | 0 (50%) |
| Company Name | Melodiol Global Health Ltd |
| Address |
suite 5 nedlands, western australia 6009 |
| Website | https://www.cresopharma.com |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
